NCT01316510

Brief Summary

Infants born with gastroschisis usually require surgery shortly after birth. After surgery the intestine is often unable to digest human milk or formula for weeks or months. During this time the baby has to remain in the hospital to receive special nutrition through an IV. How bacteria colonize the intestine in these babies is unknown. Probiotics are bacteria that appear to have beneficial effects on digestion. This study will test whether giving probiotic bacteria to babies after surgery for gastroschisis will change the bacteria in the intestine to be more like those of a healthy breast-fed baby.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2011

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

March 14, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 16, 2011

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
3 years until next milestone

Results Posted

Study results publicly available

July 13, 2018

Completed
Last Updated

July 13, 2018

Status Verified

October 1, 2017

Enrollment Period

3.9 years

First QC Date

March 14, 2011

Results QC Date

July 14, 2016

Last Update Submit

October 3, 2017

Conditions

Keywords

Probioticbifidobacteriaintestinal motility

Outcome Measures

Primary Outcomes (1)

  • Composition of the Fecal Microbiota

    Stools will be collected from messy diapers. Percentage bifidobacteria = total bifidobacteria per Group divided by the total bacteria per Group multiplied by 100% Percentage clostridia = total clostridia per Group divided by the total bacteria per Group multiplied by 100%

    Final stool sample at 6 weeks

Secondary Outcomes (1)

  • Length of Hospital Stay

    Initial discharge from the hospital

Study Arms (2)

Bifidobacteria infantis

ACTIVE COMPARATOR

1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)

Dietary Supplement: Bifidobacteria infantis

Placebo

PLACEBO COMPARATOR

A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).

Other: Placebo

Interventions

Bifidobacteria infantisDIETARY_SUPPLEMENT

1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge

Bifidobacteria infantis
PlaceboOTHER

Dilute Nutramigen formula

Placebo

Eligibility Criteria

AgeUp to 2 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Gastroschisis
  • Born at or transferred to UC Davis Children's hospital

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UC Davis Children's Hospital

Sacramento, California, 95817, United States

Location

Related Publications (1)

  • Powell WT, Borghese RA, Kalanetra KM, Mirmiran M, Mills DA, Underwood MA. Probiotic Administration in Infants With Gastroschisis: A Pilot Randomized Placebo-Controlled Trial. J Pediatr Gastroenterol Nutr. 2016 Jun;62(6):852-857. doi: 10.1097/MPG.0000000000001031.

MeSH Terms

Conditions

Gastroschisis

Condition Hierarchy (Ancestors)

Musculoskeletal AbnormalitiesMusculoskeletal DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHernia, AbdominalHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Mark Underwood
Organization
UC Davis

Study Officials

  • Mark A Underwood, MD

    UC Davis

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 14, 2011

First Posted

March 16, 2011

Study Start

March 1, 2011

Primary Completion

February 1, 2015

Study Completion

August 1, 2015

Last Updated

July 13, 2018

Results First Posted

July 13, 2018

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share

Locations